Jaguar health subsidiary receiving preclinical services from the national institute of allergy and infectious diseases for new preclinical study initiated january 6, 2021 for lechlemer plant-based drug candidate for the symptomatic relief of diarrhea from cholera

Lechlemer development focused on possible tropical disease priority review voucher san francisco, ca / accesswire / january 6, 2021 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") announced today that the 28-day preclinical toxicology and safety study in dogs began today, january 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of napo pharmaceuticals ("napo"), jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera. as previously announced, napo is receiving preclinical services from the national institute of allergy and infectious diseases ("niaid") to support lechlemer development.
JAGX Ratings Summary
JAGX Quant Ranking